Ohana is pioneering a reproductive health revolution through its industry-first platform of sperm-based technologies.

We are a group of experienced drug developers, computational biologists, sperm biology experts and successful commercial leaders. We began with a vision to reimagine global reproductive health and help people at every point in their reproductive journey.

Our unprecedented understanding of sperm biology coupled with our pioneering technologies will turn our vision into a reality

Our platform is a unique combination of biology and technology never before applied to reproductive health which has revealed breakthrough discoveries that impact the most important aspects of the reproductive journey. Our programs address three fundamental components of reproductive health: fertility, pregnancy and child health, and contraception. By offering advancements in fertility treatments; new technologies to reduce pregnancy complications, developmental disorders and inherited disease; and non-hormonal contraception, Ohana is positioned to become a leader in reproductive health, offering life-changing options for people.

Ohana was founded in 2016 by Flagship Pioneering and is based in Cambridge, Mass.

Leadership Team

amber salzman photo

Amber Salzman, PhD

President and Chief Executive Officer

alka batycky photo

Alka Batycky, PhD

Vice President, Clinical Strategy & Operations

lance colwell photo

Lance Colwell, BS

Chief Operating Officer

caren deardorf photo

Caren B. Deardorf, BS, MBA

Chief Commercial Officer

eric furfine photo

Eric Furfine, PhD

Chief Scientific Officer

dave mcmanus photo

David McManus, BBA, CPA

Vice President of Finance, Treasurer and Secretary

Sarah O’Brien photo

Sarah O’Brien, BA

Vice President, Head of People & Organization

Kathleen Seyb photo

Kathleen Seyb, PhD

Vice President, Research

Brendan St. Amant photo

Brendan St. Amant, JD, MPP

Vice President, Legal

Board of Directors

David Berry, MD, PhD

​General Partner, Flagship Pioneering;
Founder, Ohana Biosciences

Claire M. Fraser, PhD

Director of the Institute for Genome Sciences
(University of Maryland School of Medicine in Baltimore)

John Mendlein, PhD, JD

Executive Partner, Flagship Pioneering;
Chairman of the Board, Ohana Biosciences

Michael Rosenblatt, MD

Chief Medical Officer, Flagship Pioneering

David Sable, MD (ObGyn, Reproductive Endocrinologist)

Life Sciences Portfolio Manager,
Special Situations Life Funds

Amber Salzman, PhD

President and Chief Executive Officer,
Ohana Biosciences

Gregory L. Summe, MS, MBA

Managing Partner, Glen Capital Partners